Technical Analysis for RCUS - Arcus Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 15.30 | 0.46% | 0.07 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Hammer Candlestick | Bullish | 0.46% | |
Pocket Pivot | Bullish Swing Setup | 0.46% | |
Bollinger Band Squeeze | Range Contraction | 0.46% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.46% | |
Lower Bollinger Band Touch | Weakness | 0.46% | |
Oversold Stochastic | Weakness | 0.46% |
Alert | Time |
---|---|
Possible NR7 | about 6 hours ago |
60 Minute Opening Range Breakdown | about 8 hours ago |
Down 1% | about 9 hours ago |
Hammer Candlestick Entry | about 10 hours ago |
Rose Above Previous Day's High | about 10 hours ago |
Get a Trading Assistant
- Earnings date: 08/05/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 25.47 |
52 Week Low | 12.96 |
Average Volume | 753,403 |
200-Day Moving Average | 16.64 |
50-Day Moving Average | 15.94 |
20-Day Moving Average | 15.94 |
10-Day Moving Average | 15.78 |
Average True Range | 0.80 |
RSI (14) | 42.86 |
ADX | 14.62 |
+DI | 18.06 |
-DI | 23.01 |
Chandelier Exit (Long, 3 ATRs) | 14.77 |
Chandelier Exit (Short, 3 ATRs) | 17.10 |
Upper Bollinger Bands | 16.97 |
Lower Bollinger Band | 14.92 |
Percent B (%b) | 0.19 |
BandWidth | 12.89 |
MACD Line | -0.20 |
MACD Signal Line | -0.09 |
MACD Histogram | -0.1058 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 16.05 | ||||
Resistance 3 (R3) | 16.02 | 15.75 | 15.93 | ||
Resistance 2 (R2) | 15.75 | 15.56 | 15.76 | 15.88 | |
Resistance 1 (R1) | 15.52 | 15.44 | 15.64 | 15.55 | 15.84 |
Pivot Point | 15.25 | 15.25 | 15.30 | 15.26 | 15.25 |
Support 1 (S1) | 15.02 | 15.06 | 15.14 | 15.05 | 14.76 |
Support 2 (S2) | 14.75 | 14.94 | 14.76 | 14.72 | |
Support 3 (S3) | 14.52 | 14.75 | 14.68 | ||
Support 4 (S4) | 14.55 |